Leukeran (Chlorambucil)

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as an oral tablet for oral use. It is employed in the treatment of certain leukemias and lymphomas in adult patients, including chronic lymphocytic leukemia, Hodgkin's lymphoma and non‑Hodgkin's lymphoma.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with reliable logistics and regulatory support for cross‑border procurement. Our network ensures timely delivery and compliance with local import requirements. We maintain strict quality assurance throughout the supply chain.

Leukeran is an alkylating chemotherapy used to treat malignancies of the lymphoid and myeloid systems.

- Chronic lymphocytic leukemia (CLL): helps control disease progression and prolongs survival in adult patients. - Hodgkin's lymphoma: used as part of combination therapy to achieve remission. - Non‑Hodgkin's lymphoma: contributes to disease control in indolent subtypes. - Polycythemia vera: reduces elevated red blood cell mass and mitigates thrombotic risk. - Other indolent lymphoid malignancies: provides therapeutic benefit where other options are limited.

Leukeran may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fatigue and loss of appetite - Bone marrow suppression (e.g., leukopenia, anemia) - Alopecia (hair loss)

Serious or Rare Side Effects: - Secondary malignancies (e.g., acute leukemia) - Severe infections due to profound neutropenia - Pulmonary fibrosis or interstitial lung disease - Hepatic or renal toxicity leading to organ dysfunction

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for toxicity.

- Monitor blood counts regularly: detect bone marrow suppression early. - Assess liver function before and during therapy: adjust if hepatic impairment. - Evaluate renal function: dose may need modification in renal insufficiency. - Avoid use in pregnancy: drug is teratogenic (Category D) and requires effective contraception. - Use contraception during treatment and for several months after: prevent fetal exposure. - Adjust dose in hepatic impairment: follow prescriber guidance. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Chlorambucil can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Other alkylating agents: additive bone marrow toxicity. - Live vaccines: risk of infection due to immunosuppression. - Strong CYP450 inducers (e.g., phenobarbital): may reduce chlorambucil effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: chlorambucil may increase INR; monitor coagulation parameters. - Allopurinol: may raise chlorambucil plasma levels; observe for heightened toxicity.